Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01709110 · ClinicalTrials.gov registry record · Phase 4
VERtebral Fracture Treatment Comparisons in Osteoporotic Women
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,366
- Enrollment target
NCT01709110 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,366 participants.
The verdict
NCT01709110, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,366 participants
- Enrollment target
Study Summary
The primary purpose of participation in this study is to answer whether teriparatide is superior to risedronate in reducing the occurrence of new vertebral fractures during 24 months of therapy.
Interventions
- DRUG Placebo
- DRUG Risedronate
- DRUG Teriparatide
- DRUG Calcium
- DRUG Vitamin D
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,366 participants |
| Start Date | 2012-10 |
| Est. Completion | 2016-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01709110
The ClinicalTrials.gov registry entry for NCT01709110 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,366 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01709110 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01709110 about?
NCT01709110 is a clinical study titled "VERtebral Fracture Treatment Comparisons in Osteoporotic Women". The primary purpose of participation in this study is to answer whether teriparatide is superior to risedronate in reducing the occurrence of new vertebral fractures during 24 months of therapy.
What is the current status of trial NCT01709110?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,366 participants. The study started on 2012-10. Estimated completion is 2016-07.
What interventions are being tested in trial NCT01709110?
The interventions under investigation include: Placebo (DRUG), Risedronate (DRUG), Teriparatide (DRUG), Calcium (DRUG), Vitamin D (DRUG).
Who is sponsoring clinical trial NCT01709110?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.